A phase II trial on efficacy and safety of osimertinib in elderly EGFR T790M-positive non-small-cell lung cancer patients who progressed during prior EGFR-TKI treatment or had recurrence
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 12 Jul 2018
At a glance
- Drugs Osimertinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms SPIRAL Study
- 05 Jul 2018 Status changed from recruiting to active, no longer recruiting.
- 05 Jul 2018 Trial design published in the Medicine.
- 08 Sep 2016 Status changed from not yet recruiting to recruiting.